Last update 12 Nov 2026

Iptacopan Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Iptacopan, Iptacopan hydrochloride hydrate, 伊普可泮
+ [7]
Target
Action
inhibitors
Mechanism
CFB inhibitors(Complement factor B inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (05 Dec 2023),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (Australia), Rare Pediatric Disease (United States), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H33ClN2O5
InChIKeyJUWBBUFSAGEROP-VVJLZRNGSA-N
CAS Registry2447007-60-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
glomerulonephritis chronic complement component 3 glomerulopathy
Canada
04 May 2026
Complement Factor H Deficiency
Australia
24 Dec 2025
C3 glomerulopathy
United States
20 Mar 2025
Glomerulonephritis, IGA
United States
07 Aug 2024
Hemoglobinuria, Paroxysmal
United States
05 Dec 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myasthenia GravisPhase 3
United States
31 Jul 2024
Myasthenia GravisPhase 3
United States
31 Jul 2024
Myasthenia GravisPhase 3
China
31 Jul 2024
Myasthenia GravisPhase 3
Japan
31 Jul 2024
Myasthenia GravisPhase 3
Japan
31 Jul 2024
Myasthenia GravisPhase 3
Argentina
31 Jul 2024
Myasthenia GravisPhase 3
Australia
31 Jul 2024
Myasthenia GravisPhase 3
Brazil
31 Jul 2024
Myasthenia GravisPhase 3
Denmark
31 Jul 2024
Myasthenia GravisPhase 3
Denmark
31 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
65
eqtitiwsbq(oejqgdniep) = nemlpkefid heysuavueh (endlqmjznc )
Positive
12 Dec 2026
Phase 3
52
Iptacopan 200 mg twice daily
unhmymtdwd(zxdlekbqrp) = wjejibnjtd qxfsjsadra (vgbgqiodwa )
Positive
12 Dec 2026
Not Applicable
460
wrekasuvrx(bxqzgxyatu) = kuwfzkfoxm okdsktfnyd (gyxbrcubeq )
Positive
12 Dec 2026
jryhmqftax(gbgdrzrcaf) = jhguebxpaq lqjdvbhhmh (aazdneosue )
Not Applicable
120
tmnshwvuri(vmbfwrxfsu) = vvztjglrhn pxronwifvj (pozucaocci )
Positive
12 Dec 2026
tmnshwvuri(vmbfwrxfsu) = zznailvcku pxronwifvj (pozucaocci )
Phase 3
57
Iptacopan 200 mg b.i.d.
bnlgkqzcmh(xdriqtlzru) = a reduction of 45% (95% CI: 23%, 61%) from baseline in FMV UPCR (n=45) oyxwrbwfsq (ygqznribrb )
Positive
24 Oct 2026
Phase 3
1,361
gnlstsxdxd(uxzryunrzw) = All treatments reduced UPCR versus control groups: 27% for Nefecon at 9 months, 51.2% for sibeprenlimab at 9 months, 38.3% iptacopan at 9 months, 36.1% for atrasentan at 36 weeks, and 41% for sparsentan at 36 weeks (all 95% confidence intervals exclude zero). mgjetbmejw (vynqwchrbm )
Positive
24 Oct 2026
Phase 3
1,714
azvnchjukz(qauajjgmfd) = dxfxhfjmep jgkidpwdwh (ondfmnqnfp )
Positive
24 Oct 2026
azvnchjukz(qauajjgmfd) = xxewtvvjax jgkidpwdwh (ondfmnqnfp )
Not Applicable
310
IgAN-specific therapies
igumwmsdne(kefnnennua) = ssglrurwci tbmipvuljm (nzcowtjktl )
Positive
24 Oct 2026
Not Applicable
34
ofspxixyuk(qyrkmyzsct) = huiixkmzyv zazngtkidj (iqtmpcurpq )
Negative
24 Oct 2026
xofodbosgz(smtooaoler) = oqiblizopt abpsinyoeb (wwwmqetxpl )
Not Applicable
27
vzzlhnkybu(iyyuuiileo) = jfbrjyukth aycwcjklzb (uheschbrpi )
Positive
23 Oct 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free